Introduction To Adaptive Trial Designs And Master Protocols
Download and Read Introduction To Adaptive Trial Designs And Master Protocols full books in PDF, ePUB, and Kindle. Read online free Introduction To Adaptive Trial Designs And Master Protocols ebook anywhere anytime directly on your device. We cannot guarantee that every ebooks is available!
Introduction to Adaptive Trial Designs and Master Protocols
| Author | : Jay J. H. Park |
| Publisher | : Cambridge University Press |
| Total Pages | : 189 |
| Release | : 2023-03-31 |
| Genre | : Medical |
| ISBN | : 1108926983 |
Download Introduction to Adaptive Trial Designs and Master Protocols Book in PDF, Epub and Kindle
A unique and practical high-level introductory guide to the emerging field of adaptive trial designs, platform trials, and master protocols.
Introduction to Adaptive Trial Designs and Master Protocols Related Books
Language: en
Pages: 189
Pages: 189
Type: BOOK - Published: 2023-03-31 - Publisher: Cambridge University Press
A unique and practical high-level introductory guide to the emerging field of adaptive trial designs, platform trials, and master protocols.
Language: en
Pages: 226
Pages: 226
Type: BOOK - Published: 2015-05-21 - Publisher: CRC Press
All the Essentials to Start Using Adaptive Designs in No TimeCompared to traditional clinical trial designs, adaptive designs often lead to increased success ra
Language: en
Pages: 284
Pages: 284
Type: BOOK - Published: 2010-06-15 - Publisher: John Wiley & Sons
ExpDesign Studio facilitates more efficient clinical trial design This book introduces pharmaceutical statisticians, scientists, researchers, and others to ExpD
Language: en
Pages: 420
Pages: 420
Type: BOOK - Published: 2014-10-15 - Publisher: Springer
This edited volume is a definitive text on adaptive clinical trial designs from creation and customization to utilization. As this book covers the full spectrum
Language: en
Pages: 321
Pages: 321
Type: BOOK - Published: 2020-11-11 - Publisher: CRC Press
In the United States, a rare disease is defined by the Orphan Drug Act as a disorder or condition that affects fewer than 200,000 persons. For the approval of "
